Emapalumab

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
Emapalumab
Monoclonal antibody
Type Whole antibody
Source Human
Target IFN-gamma
Clinical data
Synonyms NI-0501
Routes of
administration
IV, parenteral
ATC code
  • none
Identifiers
CAS Number
ChemSpider
  • none
UNII
Chemical and physical data
Formula C6430H9898N1718O2038S46
Molar mass 154.4 g/mol

Emapalumab (NI-0501)[1] is an experimental drug in development by Novimmune. It is an anti-IFNγ antibody for the treatment of hemophagocytic lymphohistiocytosis,[2] which currently has no cure.[3]

A phase II/III trial began in 2013 and is ongoing.[4] The trial targets patients under the age of 18 who have failed to improve on conventional treatments.[5]. This study was realised in the context of an EU-funded FP7 project, named FIGHT-HLH (306124)

The FDA awarded orphan drug status in 2012, and breakthrough therapy designation in 2016 on the basis of preliminary data from the phase II trial.[6][7]


References[edit]